文献速递造血干细胞移植与细胞治疗淋巴瘤

单核-巨噬细胞谱系对免疫治疗结局的贡献

The contribution of the monocyte-macrophage lineage to immunotherapy outcomes.
PubMed 文献 · Blood · 2025-01-01

本文综述巨噬细胞在组织稳态与疾病中的作用,重点讨论慢性移植物抗宿主病(cGVHD)中CSF1依赖的供者来源巨噬细胞驱动皮肤和肺纤维化,以及抗体阻断CSF1R清除巨噬细胞在临床前模型和临床试验中的效果,并探讨该策略用于增强免疫检查点抑制反应和减轻CAR-T毒性的潜力。

要点

  • CSF1依赖的供者来源巨噬细胞是cGVHD纤维化皮肤和肺病的关键致病介质。
  • 抗体阻断CSF1R清除巨噬细胞在临床前模型预防纤维化,临床试验中改善cGVHD疗效显著。
  • 巨噬细胞清除策略正在研究用于增强免疫检查点抑制反应,并可能干预CAR-T相关毒性。

核心结论

  • 靶向CSF1/CSF1R信号轴清除巨噬细胞是改善cGVHD及可能增强免疫治疗疗效的潜在治疗策略。

研究设计与样本

  • 本文为综述,检索并汇总巨噬细胞基础生物学及其在细胞治疗和免疫治疗中作用的相关文献。

主要发现

  • 在cGVHD中,CSF1依赖的供者来源巨噬细胞被确定为纤维化皮肤和肺病的关键致病介质。
  • 抗体阻断CSF1R诱导巨噬细胞清除在临床前模型中显示出预防纤维化的显著能力。
  • CSF1R抗体阻断在正在进行的临床试验中显示出改善cGVHD的显著疗效。
  • 单核细胞和组织驻留巨噬细胞群体近期被牵涉为CAR-T细胞治疗相关多种毒性的介质。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Macrophages execute core functions in maintaining tissue homeostasis, in which their extensive plasticity permits a spectrum of functions from tissue remodeling to immune defense. However, perturbations to tissue-resident macrophages during disease, and the subsequent emergence of monocyte-derived macrophages, can hinder tissue recovery and promote further damage through inflammatory and fibrotic programs. Gaining a fundamental understanding of the critical pathways defining pathogenic macrophage populations enables the development of targeted therapeutic approaches to improve disease outcomes. In the setting of chronic graft-versus-host disease (cGVHD), which remains the major complication of allogeneic hematopoietic stem cell transplantation, colony-stimulating factor 1 (CSF1)-dependent donor-derived macrophages have been identified as key pathogenic mediators of fibrotic skin and lung disease. Antibody blockade of the CSF1 receptor (CSF1R) to induce macrophage depletion showed remarkable capacity to prevent fibrosis in preclinical models and has subsequently demonstrated impressive efficacy for improving cGVHD in ongoing clinical trials. Similarly, macrophage depletion approaches are currently under investigation for their potential to augment responses to immune checkpoint inhibition. Moreover, both monocyte and tissue-resident macrophage populations have recently been implicated as mediators of the numerous toxicities associated with chimeric antigen receptor T-cell therapy, further highlighting potential avenues of macrophage-based interventions to improve clinical outcomes. Herein, we examine the current literature on basic macrophage biology and contextualize this in the setting of cellular and immunotherapy. Additionally, we highlight mechanisms by which macrophages can be targeted, largely by interfering with the CSF1/CSF1R signaling axis, for therapeutic benefit in the context of both cellular and immunotherapy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Adams RC, MacDonald KPA, Hill GR, et al. The contribution of the monocyte-macrophage lineage to immunotherapy outcomes. Blood. 2025. PMID: 39576958. doi:10.1182/blood.2024025680

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。